| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Purpan College of Agriculture, and 2 National Institute for Agronomic Research, Neuro-Gastroenterology and Nutrition Unit, Toulouse, and 3 Pfizer Global R&D, Fresnes, France
CORRESPONDENCE: H. Eutamene, INRA, Neuro-Gastroenterology and Nutrition Unit, 180 chemin de Tournefeuille, B.P. 3, 31931 Toulouse, France. Fax: 33 561285145. E-mail: heutamen@toulouse.inra.fr
Keywords: Airway epithelium, inflammation, lipopolysaccharide, lung, myosin light chain kinase, permeability
Received: June 2, 2004
Accepted December 29, 2004
The respiratory system is directly exposed to low levels of lipopolysaccharide (LPS), present as a contaminant on airborne particles. In cystic fibrosis, the prevailing data identify structural changes of the airway epithelium, as well as tight junction dilatation. This study was aimed at determining the contribution of myosin light chain kinase to maintaining airway epithelium barrier integrity in the lung inflammatory response to LPS in rats.
The effects of the selective myosin light chain kinase inhibitor, 5-iodonaphthalene-1-sulphonyl-homopiperazine (ML-7), were evaluated: 1) on pulmonary inflammation and airway epithelium barrier permeability alterations induced by intra-tracheal LPS from Pseudomonas aeruginosa; and 2) on levels of the phosphorylated form of the myosin light chain, which is increased in a human airway epithelial cell line (NCI-H292) and tracheal tissue after LPS exposure.
The results show that LPS increased airway epithelium barrier paracellular permeability and lung inflammation, and that pre-treatment with ML-7 inhibited both effects. This effect of ML-7 was associated with the inhibition of phosphorylated myosin light chain in both NCI-H292 cells and tracheal tissue.
The data, obtained using in vivo and in vitro approaches, demonstrate a key role for myosin light chain kinase in lung inflammation, and suggest that myosin light chain kinase could be a potential target for novel drugs intended for relief of lung injury.
This article has been cited by other articles:
|
|
 |
|
  R. Kamp, X. Sun, and J. G. N. Garcia Making Genomics Functional: Deciphering the Genetics of Acute Lung Injury Proceedings of the ATS, April 15, 2008; 5(3): 348 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sheth, N. Delos Santos, A. Seth, N. F. LaRusso, and R. K. Rao Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBP-dependent mechanism Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G308 - G318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Ranaivo, N. Carusio, R. Wangensteen, P. Ohlmann, C. Loichot, A. Tesse, K. Chalupsky, I. Lobysheva, J. Haiech, D. M. Watterson, et al. Protection Against Endotoxic Shock as a Consequence of Reduced Nitrosative Stress in MLCK210-Null Mice Am. J. Pathol., February 1, 2007; 170(2): 439 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Shin, C. P. Shelburne, C. Jin, E. A. LeFurgey, and S. N. Abraham Harboring of Particulate Allergens within Secretory Compartments by Mast Cells following IgE/Fc{epsilon}RI-Lipid Raft-Mediated Phagocytosis J. Immunol., November 1, 2006; 177(9): 5791 - 5800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cuzzocrea, G. Nocentini, R. Di Paola, M. Agostini, E. Mazzon, S. Ronchetti, C. Crisafulli, E. Esposito, A. P. Caputi, and C. Riccardi Proinflammatory Role of Glucocorticoid-Induced TNF Receptor-Related Gene in Acute Lung Inflammation J. Immunol., July 1, 2006; 177(1): 631 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bals Lipopolysaccharide and the lung: a story of love and hate Eur. Respir. J., May 1, 2005; 25(5): 776 - 777. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
